Date: Mar 16, 2017
Rick Stearns was quoted in the March 16 Law 360 Article "Trump's Hiking of FDA User Fees Unlikely to Speed Approvals." The article discusses how the White House 2018 budget calls for doubling the fees from companies for the review of drugs and medical devices, and questions whether this measure will support the president's goal of a speedier approval process. Citing industry's satisfaction with the current timeframes, Rick indicated that higher fees may actually hinder innovation by pricing small companies out of the approval process. To read the full article, click here. Please note that Law 360 is available by subscription only.